OTC · Drug Manufacturers - Specialty & Generic

Eagle Pharmaceuticals, Inc. (EGRX) Stock

$0.37 -15.91% OTC: EGRX Healthcare

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.

Valuation

MetricValue
Price$0.37
Market Cap$4.87M
P/E Ratio0.13
P/B Ratio0.02
P/S Ratio0.02
EPS (TTM)$2.85
52-Week High$3.87
52-Week Low$0.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE17.39%
ROA8.78%
ROCE27.44%
Gross Margin70.01%
Operating Margin25.57%
Net Margin11.26%
Debt/Equity0.29
Current Ratio1.70

Annual Financials (USD)

Metric20192020202120222023
Revenue$196.0M$188.0M$172.0M$317.0M—
Operating Profit$22.0M$33.0M$3.0M$81.0M—
Net Profit$14.0M$12.0M$-9.0M$36.0M—
EPS$1.01$0.87$-0.66$2.73—
Op Margin11.1%17.6%1.6%25.6%—

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$255.0M$253.0M$254.0M$406.0M—
Total Liabilities$75.0M$67.0M$77.0M$173.0M—
Cash$110.0M$103.0M$98.0M$55.0M—
Borrowings$39.0M$38.0M$30.0M$68.0M$0

Latest News

Corebridge Financial, Equitable Stockholders Approve Merger MT Newswires · Jul 30, 2026 Morgan Stanley warns SpaceX approaching its most dangerous moment TheStreet · Jul 30, 2026 Exchange-Traded Funds Higher as US Equities Advance After Midday MT Newswires · Jul 30, 2026 Independence Gold Finds New Dixie Vein Near Tommy Vein System in British Columbia MT Newswires · Jul 30, 2026 Jersey Mike's stock opens at $21 per share, valuing the sandwich chain just shy of $1 billion Yahoo Finance · Jul 30, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$56.0M$49.0M$28.0M$51.0M$31.0M
Investing Cash Flow$-2.0M$-19.0M$-6.0M$-87.0M$0
Financing Cash Flow$-18.0M$-33.0M$-20.0M$-19.0M$0
Net Cash Flow$31.0M$-7.0M$-5.0M$-42.0M$31.0M
Free Cash Flow$55.0M$49.0M$28.0M$51.0M$31.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.22
FCF Yield632.60%
Quick Ratio1.27
Interest Coverage20.01
Return 1Y-89.97%
Return 3Y-98.01%
Return 5Y-99.21%

Ownership

Insiders Held0.00%
Institutions Held54.77%
Institutions Float Held54.77%
Institutional HolderSharesReport Date
Stanley-Laman Group, Ltd.12,0002026-03-31
Archer Investment Corp3502026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BLMHBlum Holdings, Inc. $0.17 -8.84% -0.37 $2.24M 0.00%
CLCFFChristina Lake Cannabis Corp. $0.02 +0.00% -2.27 $4.22M 0.00%
CNFHFCanaFarma Hemp Products Corp. $0.00 — 0.00 $19561 0.00%
ECGSEco-Growth Strategies Inc. $0.04 -23.21% -2.54 $2.45M 0.00%
MCUJFMedicure Inc. $0.67 -16.72% -1.61 $7.04M 0.00%

About Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Eagle Pharmaceuticals, Inc. is headquartered in US.

Eagle Pharmaceuticals, Inc. (EGRX) stock trades at $0.37 with a market capitalization of $4.87M. The stock is valued at a price-to-earnings (P/E) ratio of 0.13, price-to-book of 0.02, price-to-sales of 0.02. Over the past 52 weeks the stock has ranged between $0.06 and $3.87, and currently trades 90.4% below its 52-week high.

On profitability, Eagle Pharmaceuticals, Inc. generates a return on equity (ROE) of 17.39%, above the typical market average, return on capital employed of 27.44%, an operating margin of 25.57%, a net profit margin of 11.26%.

Official website: www.eagleus.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides